A leading cancer charity has hit out at an insurer's decision to exclude a new bowel cancer treatment from its PMI policies and fears that others will follow suit.
In a letter seen by Money Marketing, Norwich Union Healthcare tells a consultant that it will not pay out for cancer patients who need a certain chemotherapy treatment.
The letter says that Cetuximab monotherapy, which is used to treat bowel cancer, is not eligible for benefit on NU Healthcare policies. The letter says the chemotherapy does not meet the provider's definition of “treatment” for the purposes of the policy.
Cancer Bacup spokeswoman Jill Morrell says this is a worrying shift.
NU argues that the relatively new drug is not used to “cure” cancer as it does not kill cancer cells but to encourage long-term stabilisation of the disease.
Morrell says: ” This drug is not a palliative, it controls the development of cancer cells. It is a modern short-term treatment. At the very least, if insurers are not going to pay out for it they should make it clear from the outset.”